Pharmacokinetics Program

自1983年药代动力学共享资源成立以来，核心的主要使命为 促进高质量的竞争性资助的同行评审药代动力学/药效学 SJ癌症中心的临床和临床前模型转化研究。目标是：（1） 通过协助研究设计，在圣犹达癌症中心实施药代动力学研究试验， 建立标准医嘱和实验室检测程序，并对护理和其他临床工作人员进行教育2） 有效和适当地收集、登记、处理和分发这些试验的药代动力学样本， 3)确保对抗癌药物、其代谢物或其他药物进行有效、高质量的灵敏度和特异性分析， 生物样品中的相关药理学指标，并协助最先进的生物医学 药代动力学和药效学建模。药代动力学共享资源的益处， 癌症中心包括：成本效益，最先进设备、设施 药代动力学/动力学项目的方法， 连续的、完整记录的分析质量控制，集中的样品处理和储存， 将资源集中在一个设施内，尽量减少对儿童的侵入性采集程序， 最大限度地减少用于临床前研究的动物数量，并促进科学合作。 自上次竞争性更新以来，共享资源的LC-MS容量已大大增强。一 收费系统已经启动，正在分阶段实施，以适用于资源公司处理的所有样品。一个 Crews博士加入了一个内联网网站，其中明确解释了退款和提供的服务 2005年7月，作为共同主任使用共享资源，监督核心小组的日常活动。贝克博士 我于2006年8月加入核心，并将接任此次更新的共享资源主任 Relling博士将继续作为顾问参与，以确保领导层的无缝过渡。

Since the founding of the Pharmacokinetics Shared Resource in 1983, the primary mission of the Core has been to facilitate high-quality competitively funded peer-reviewed pharmacokinetic/pharmacodynamic translational research in both clinical and pre-clinical models at the SJ Cancer Center. The objectives are to 1) implement trials with pharmacokinetic studies at the St. Jude Cancer center by assisting with study design, building of standard orders and laboratory test procedures, and educating nursing and other clinical staff 2) efficiently and properly collect, accession, process, and distribute pharmacokinetic samples on these trials and 3) ensure valid, high quality sensitive and specific analyses of anticancer drugs, their metabolites, or other relevant pharmacologic indices in biological samples, and assist with state-of-the-art biomedical pharmacokinetic and pharmacodynamic modelling. The benefits of the Pharmacokinetics Shared Resource to the Cancer Center include: cost-efficiency, consistency in application of state-of-the-art equipment, facilities, and approaches to pharmacokinetic/dynamic projects, standardized operating procedures for regimented, continuous, and thoroughly documented analytical quality control, centralized sample processing and storage, consolidation of resources in a single facility, minimization of invasive collection procedures in children and minimizing the number of animals for preclinical studies, and stimulation of scientific collaborations. Since the last competitive renewal, the LC-MS capacity of the Shared Resource has been greatly enhanced. A chargeback system was begun and is being phased in to apply to all samples processed by the Resource. An intranet site was established with clear explanations for chargebacks and services provided, Dr. Crews joined the shared resource in July 2005 as Co-Director to supervise the day-to-day activities of the core. Dr. Baker joined the core in August 2006 and will take over as Director of the shared resource for this renewal application; Dr. Relling will remain involved as a consultant to ensure a seamless transition in leadership.